Literature DB >> 27280345

A Simple Modification to the Mosquito Homogenization Protocol Safely Inactivates West Nile Virus and Allows Virus Detection by the Rapid Analyte Measurement Platform (RAMP®) ASSAY.

Kristen L Burkhalter1, Brad J Biggerstaff1, Kalanthe Horiuchi1, Harry M Savage1.   

Abstract

We evaluated the ability of the Rapid Analyte Measurement Platform (RAMP(®)) mosquito-grinding buffer to inactivate West Nile virus (WNV) by subjecting WNV-positive samples ground in RAMP buffer to incubation intervals ranging from 5 min to 60 min. At each time point an aliquot was removed and serially diluted in bovine albumin (BA)-1 cell culture media to stop the inactivation process by RAMP buffer. Each BA-1 sample was tested for viable virus using Vero 6-well cell culture plaque assay and observed for plaques. We observed very limited inactivation of WNV (1-2 log10 plaque-forming units/ml) by RAMP buffer. Concerned for RAMP operators who may be using this assay in low-level biocontainment facilities, we developed an alternate sample homogenization protocol using Triton X-100 detergent that ensures complete WNV inactivation without compromising the performance of the RAMP assay.

Entities:  

Keywords:  Mosquito; RAMP® test; Triton X-100; West Nile virus; virus inactivation

Mesh:

Year:  2016        PMID: 27280345      PMCID: PMC7111560          DOI: 10.2987/moco-32-02-77-82.1

Source DB:  PubMed          Journal:  J Am Mosq Control Assoc        ISSN: 8756-971X            Impact factor:   0.917


  12 in total

1.  Transmission of dengue virus without a mosquito vector: nosocomial mucocutaneous transmission and other routes of transmission.

Authors:  Lin H Chen; Mary E Wilson
Journal:  Clin Infect Dis       Date:  2004-08-30       Impact factor: 9.079

2.  Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.

Authors:  Peter L Roberts
Journal:  Biologicals       Date:  2008-09       Impact factor: 1.856

3.  Arbovirus infections among laboratory personnel in Ibadan, Nigeria.

Authors:  O Tomori; T P Monath; E H O'Connor; V H Lee; C B Cropp
Journal:  Am J Trop Med Hyg       Date:  1981-07       Impact factor: 2.345

4.  Chikungunya virus and the safety of plasma products.

Authors:  Sandra M Leydold; Maria R Farcet; Johanna Kindermann; Jens Modrof; Gerhard Pölsler; Andreas Berting; M Keith Howard; P Noel Barrett; Thomas R Kreil
Journal:  Transfusion       Date:  2012-02-17       Impact factor: 3.157

5.  Evaluation of a rapid analyte measurement platform and real-time reverse-transcriptase polymerase chain reaction assay West Nile virus detection system in mosquito pools.

Authors:  Kristen L Burkhalter; Kalanthe Horiuchi; Brad J Biggerstaff; Harry M Savage; Roger S Nasci
Journal:  J Am Mosq Control Assoc       Date:  2014-03       Impact factor: 0.917

6.  West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data.

Authors:  Thomas R Kreil; Andreas Berting; Otfried Kistner; Johanna Kindermann
Journal:  Transfusion       Date:  2003-08       Impact factor: 3.157

7.  Thermal stability and inactivation of hepatitis C virus grown in cell culture.

Authors:  Hongshuo Song; Jin Li; Shuang Shi; Ling Yan; Hui Zhuang; Kui Li
Journal:  Virol J       Date:  2010-02-18       Impact factor: 4.099

Review 8.  Laboratory-associated infections and biosafety.

Authors:  D L Sewell
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

9.  Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.

Authors:  B Horowitz; R Bonomo; A M Prince; S N Chin; B Brotman; R W Shulman
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

10.  West Nile virus infection and conjunctival exposure.

Authors:  Kevin Fonseca; Gerry D Prince; Jeff Bratvold; Julie D Fox; Margo Pybus; Jutta K Preksaitis; Peter Tilley
Journal:  Emerg Infect Dis       Date:  2005-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.